.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR21_DolutegravirAndRilpiviri.DolutegravirAndRilpiviri .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR21_DolutegravirAndRilpiviri.DolutegravirAndRilpiviri| name: | DolutegravirAndRilpivirine | |
| ATC code: | J05AR21 | route: | oral |
| compartments: | 1 | |
| dosage: | 50 | mg |
| volume of distribution: | 17.4 | L |
| clearance: | 1 | L/h |
| other parameters in model implementation | ||
Dolutegravir and rilpivirine is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection in adults who are virologically suppressed. Dolutegravir is an integrase strand transfer inhibitor (INSTI) and rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). This combination is currently approved and marketed.
Pharmacokinetic parameters reported in healthy adult HIV-negative volunteers after single oral administration of fixed-dose combination tablet of dolutegravir and rilpivirine.